The "GLOW Blend" is a co-packaged research combination of three separately studied compounds — GHK-Cu (a copper-binding tripeptide), BPC-157 (a synthetic pentadecapeptide), and TB-500 (an N-acetylated seven-residue fragment of thymosin beta-4) — supplied together in lyophilized form for laboratory work. It is not a single molecule, and as of 2026 no peer-reviewed controlled study has evaluated the three compounds together as a fixed combination. What the published literature does contain is a substantial and largely independent body of preclinical work on each component, and those three lines of evidence describe different, non-overlapping mechanisms: copper-dependent extracellular-matrix regulation for GHK-Cu, VEGFR2/nitric-oxide signaling for BPC-157, and G-actin sequestration and cell migration for the thymosin beta-4 fragment. This article summarizes each component's primary literature, explains what the combination evidence does and does not establish, and covers the molar-ratio and copper-chemistry considerations that matter when working with a three-peptide vial. All information is provided strictly for in-vitro and laboratory research use only.
What Is the GLOW Blend?
GLOW is an informal research-community acronym, not a regulatory or pharmacopeial designation. The vial contains three distinct lyophilized compounds in a fixed mass ratio — commonly 50 mg / 10 mg / 10 mg — rather than a single active species.
Component 1 — GHK-Cu. The tripeptide glycyl-L-histidyl-L-lysine complexed with copper(II). Supplied under CAS 300801-03-0 with a stated molecular weight of approximately 461.96 Da. Researchers should note that published molecular weights for this material vary by species: the free tripeptide GHK is approximately 340.4 Da, while copper-complexed and salt forms are reported at higher values. Confirm which species the Certificate of Analysis describes before calculating molar concentrations.
Component 2 — BPC-157. A pentadecapeptide with the sequence GEPPPGKPADDAGLV, CAS 137525-51-0, molecular weight approximately 1419.55 Da. It corresponds to a partial sequence of a protein isolated from human gastric juice.
Component 3 — TB-500. Material supplied under this research code (CAS 885340-08-9, approximately 889.01 Da) is not full-length thymosin beta-4. Native Tβ4 is a 43-residue polypeptide of roughly 4963 Da. TB-500 is the N-acetylated seven-residue actin-binding motif Ac-LKKTETQ. A COA molecular weight near 889 Da indicates the fragment; a value near 4963 Da indicates the full-length protein. This distinction matters because findings from full-length Tβ4 studies do not automatically transfer to the fragment.
GHK-Cu: The Copper-Carrier Tripeptide
GHK-Cu is the component that distinguishes GLOW from the two-peptide BPC-157/TB-500 combination, and it has the longest published history of the three.
Origin and matrix effects
GHK was originally isolated from human plasma and has affinity for copper(II) ions. The GHK triplet is present in the α2(I) chain of type I collagen, which led to the hypothesis that the tripeptide is liberated by proteases at a wound site and acts locally. Maquart and colleagues (FEBS Letters, 1988; 238(2):343–346) reported that GHK-Cu stimulated collagen synthesis in cultured fibroblasts, with the effect beginning between 10⁻¹² and 10⁻¹¹ M, maximizing near 10⁻⁹ M, and occurring independently of any change in cell number — a concentration profile more consistent with a signaling interaction than a nutritional copper effect.
The same group extended this to an in vivo model (Journal of Clinical Investigation, 1993; 92(5):2368–2376), implanting stainless-steel wire mesh cylinders subcutaneously in rats and injecting GHK-Cu or saline into the wound chamber. GHK-Cu increased extracellular matrix accumulation in the wound chambers relative to control.
Matrix remodeling, not just synthesis
A frequent oversimplification in secondary sources is that GHK-Cu simply "builds collagen." The primary literature describes bidirectional matrix regulation. Siméon and colleagues (Life Sciences, 2000; 67(18):2257–2265) reported that GHK-Cu increased MMP-2 protein in fibroblast conditioned media along with an increase in MMP-2 mRNA, and also increased secretion of the tissue inhibitors TIMP-1 and TIMP-2. Notably, the MMP-2 effect was reproduced by copper ions alone but not by the free tripeptide GHK without copper — direct evidence that the copper moiety is doing mechanistic work in this assay, not merely serving as a carrier.
Growth factor expression
Pollard and colleagues (Archives of Facial Plastic Surgery, 2005; 7(1):27–31) studied copper tripeptide in a serum-free and growth-factor-free system using primary human dermal fibroblasts explanted from irradiated and non-irradiated tissue. Treated irradiated fibroblasts approached the population-doubling time of non-irradiated controls, and produced more basic FGF and VEGF than untreated irradiated controls early after exposure.
Gene-expression scale
Broad transcriptional analyses reviewed by Pickart and Margolina (International Journal of Molecular Sciences, 2018; 19(7):1987) report that GHK modulates a large fraction of assayed human genes, with roughly 31% showing a change of 50% or greater and the direction split approximately 59% upregulated to 41% downregulated. Reviews of this kind are useful for orienting hypotheses but are not substitutes for the primary assays; the underlying datasets come from specific cell lines and exposure conditions that should be checked before generalizing.
More recent work has extended the GHK literature into fibrosis and senescence. He and colleagues (Aging Pathobiology and Therapeutics, 2024) discussed GHK modulation of myofibroblast function and integrin-β1 signaling in age-related fibrosis models, and a 2025 review in BioImpacts examined the delivery and stability problems that constrain topical GHK work — a reminder that formulation, not just mechanism, is a live research question for this compound.
BPC-157: Angiogenic and Nitric-Oxide Signaling
Hsieh and colleagues (Journal of Molecular Medicine, 2017; 95(3):323–333) reported that BPC-157 increased vessel density in vitro and in vivo and accelerated blood-flow recovery in a rat hind-limb ischemia model measured by laser Doppler scanning, with the effect associated with VEGFR2 activation and upregulation. A later report (Scientific Reports, 2020) described modulation of vasomotor tone through the Src–caveolin-1–endothelial nitric oxide synthase pathway. Both papers are rodent and cell-culture work; the compound remains an investigational tool compound with no approved indication in any jurisdiction.
TB-500 / Thymosin Beta-4 Fragment: Actin Dynamics and Migration
Native thymosin beta-4 is the principal G-actin sequestering protein in mammalian cells. Malinda and colleagues (Journal of Investigative Dermatology, 1999) reported accelerated wound closure in rodent models with Tβ4 treatment, and Philp and colleagues (FASEB Journal, 2003) identified the seven-residue actin-binding motif as sufficient to promote angiogenesis and endothelial cell migration in their assays — the finding that underpins use of the Ac-LKKTETQ fragment as a research surrogate. A 2021 review (Frontiers in Endocrinology) surveys the broader Tβ4 literature, including the caveat that fragment and full-length findings are not interchangeable.
Why These Three Are Studied Together
The rationale in the research community is mechanistic complementarity, not demonstrated pharmacological synergy. Each component is associated with a different node of the tissue-repair cascade:
| Component | Primary published mechanism | Principal readouts |
|---|---|---|
| GHK-Cu | Copper-dependent matrix regulation; MMP/TIMP balance; growth-factor expression | Collagen and GAG synthesis, MMP-2/TIMP levels, bFGF and VEGF output |
| BPC-157 | VEGFR2 upregulation; Src–caveolin-1–eNOS signaling | Vessel density, blood-flow recovery, vasomotor tone |
| TB-500 (Ac-LKKTETQ) | G-actin sequestration; cell migration | Endothelial and keratinocyte migration, wound closure rate |
Three mechanisms converging loosely on angiogenesis and matrix turnover is a reasonable hypothesis-generating rationale for a combination experiment. It is not evidence that the combination behaves additively, and there is a plausible mechanistic reason for caution: GHK-Cu both stimulates matrix synthesis and upregulates MMP-2, so a design that assumes purely additive matrix accumulation may misread the result.
What the Combination Literature Does Not Show
As of 2026, a literature search returns no controlled peer-reviewed study — in vitro or in vivo — testing GHK-Cu, BPC-157, and Ac-LKKTETQ together against each component alone. Consequently there is no published basis for claims about:
- Additive or synergistic effects of the three-compound combination
- An optimal ratio between the three components
- Comparative performance against any single component
- Any human application, outcome, or safety profile
Formulation and Molar-Ratio Considerations
A 50 mg / 10 mg / 10 mg vial is not an equimolar preparation, and treating total vial mass as a single species will produce incorrect concentrations. Using the supplied molecular weights:
- GHK-Cu: 50 mg ÷ 461.96 Da ≈ 108.2 µmol
- BPC-157: 10 mg ÷ 1419.55 Da ≈ 7.0 µmol
- Ac-LKKTETQ: 10 mg ÷ 889.01 Da ≈ 11.3 µmol
Copper chemistry in a co-dissolved system
Copper(II) is redox-active and can catalyze oxidation of susceptible amino acid side chains. It is worth noting that neither BPC-157 (GEPPPGKPADDAGLV) nor Ac-LKKTETQ contains cysteine, methionine, tryptophan, or tyrosine — the residues most vulnerable to metal-catalyzed oxidation. That reduces, but does not eliminate, the concern; copper coordination equilibria with buffer components, chelators, and serum proteins in a culture system can still alter the effective free-copper concentration and confound interpretation. Buffer choice should be reported explicitly, and researchers comparing GLOW results with single-agent GHK-Cu results should confirm the buffer systems match.
Handling, Storage, and Verification
Store the lyophilized powder at -20 °C, protected from light and moisture. Reconstitute with a sterile solvent as indicated on the Certificate of Analysis, keep reconstituted material refrigerated, and avoid repeated freeze-thaw cycles, which degrade peptide integrity. Because the vial contains three species with different molecular weights and different solution stabilities, prepare and quantify per component rather than per vial. Verify identity and purity against the COA — HPLC purity, mass-spectrometry identity confirmation, and endotoxin results where applicable — before use in any assay.
Frequently Asked Questions
What is the GLOW Blend?
A co-packaged research combination of three lyophilized compounds — GHK-Cu, BPC-157, and TB-500 — supplied together for laboratory study. It is not a single compound, not a formulated drug product, and not approved for any use in humans or animals.
What does GLOW stand for?
It is an informal research-community acronym referring to the component set. It has no regulatory or pharmacopeial meaning, and vendors do not always use it for the identical component list. Confirm the actual components and masses on the label and COA.
How does GLOW differ from the KLOW blend?
KLOW preparations add KPV, the C-terminal tripeptide fragment of α-MSH studied for melanocortin-pathway anti-inflammatory signaling, to the same three components. The two are not interchangeable in experimental design.
How does GLOW differ from the Wolverine blend?
The Wolverine combination is BPC-157 and TB-500 only. GLOW adds GHK-Cu, which introduces a copper-dependent mechanism and, as noted above, a large molar imbalance in typical 50/10/10 preparations.
Is TB-500 the same as thymosin beta-4?
No. Native Tβ4 is a 43-residue protein of about 4963 Da. Material supplied as TB-500 is the N-acetylated seven-residue actin-binding fragment Ac-LKKTETQ, approximately 889 Da. Check the COA molecular weight to confirm which species is in hand.
Does GHK need copper to be active?
In at least one assay, yes. Siméon and colleagues found that the MMP-2 stimulation attributed to GHK-Cu was reproduced by copper ions but not by the free tripeptide alone. Other reported GHK effects have been described for copper-free GHK, so the answer appears to be assay-dependent rather than universal.
Is there published evidence that the three-compound combination outperforms any single component?
No. No controlled study has tested the combination against its components. Any claim of synergy is currently a hypothesis, not a finding.
What purity does Dynamite Research Peptides supply?
Components are typically 99%+ pure by HPLC. Purity, identity, and endotoxin data are provided on the Certificate of Analysis supplied with the product.
All products are for research use only — not for human or animal consumption, and not for diagnostic or therapeutic use. Nothing in this article describes, recommends, or endorses any human or veterinary application, dosing protocol, or clinical outcome. Last updated: August 20, 2026.